Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 4Breast Neoplasms 3Recurrence 2Paraproteinemias 2Papillomavirus Infections 2Immunoglobulin Light-chain Amyloidosis 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Nodule 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Postoperative Complications 1Pneumonia 1Pancreatic Neoplasms 1Osteosarcoma 1Obesity 1Neoplasms, Plasma Cell 1Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Lung Neoplasms 1Lung Diseases, Interstitial 1Locally Advanced Breast Cancer 1Intermittent Fasting 1Hypothyroidism 1

Interventions

Rituximab 112Cyclophosphamide 103fludarabine 61Doxorubicin 33Vincristine 31Etoposide 31Prednisone 30Lenalidomide 24ibrutinib 22fludarabine phosphate 21Immunotherapy, Adoptive 19Bendamustine Hydrochloride 19obinutuzumab 18Cytarabine 18pembrolizumab 16Magnetic Resonance Spectroscopy 16Bortezomib 14Specimen Handling 13Dexamethasone 13polatuzumab vedotin 12CT-P10 12venetoclax 11Gemcitabine 11Carboplatin 11pirtobrutinib 10glofitamab 10zanubrutinib 9Nivolumab 9Mycophenolic Acid 9Melphalan 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Clinical Protocols × Clear all
NCT05744037 2023-02-24

Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells

The Affiliated Hospital of Xuzhou Medical University

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡